We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East
Monthly Production Capacity: 1000kg
Packaging Information: 25kg/drum 1kg/bottle
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/L
Product Information
Product name
Tenofovir Alafenamide Fumarate / TAF
CAS No.
1392275-56-7
Molecular Formula
2(C21H29N6O5P).C4H4O4
Molecular Weight
1069.00
Quality Standard
98% up, Medicine Grade
Appearance
White powder
COA of Tenofovir Alafenamide Fumarate / TAF
Usage
Function of Tenofovir Alafenamide Fumarate / TAF
Tenofovir Alafenamide Fumarate / TAF is a novel nucleotide reverse transcriptase inhibitor for the treatment of chronic hepatitis B virus infection and compensatory liver disease.
Tenofovir alafluamine fumarate is an oral prodrug of tenofovir (TFV), a modified version of the commercially available drug tenofovir disoproxil fumarate (TDF). Compared with TDF, TAF has a smaller clinical dose and is easier to enter the cell. The virus acts more strongly and the adverse reactions are reduced.
API TAF wasapproved by the COS on November 10, 2016 for the treatment of adult patients with chronic hepatitis B infection. PMDA was approved on December 19, 2016 and approved by EMA in 2017.1.9, becoming the first hepatitis B drug approved for listing in Europe in the past 10 years. Approved for the treatment of HIV infection, all three drugs are based on tenofovir alafenamide fumarate.
Twenty years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
